| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50037SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24877SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NB100-2530AF405 | |||
| Alexa Fluor 488 | NB100-2530AF488 | |||
| Alexa Fluor 647 | NB100-2530AF647 | |||
| Alexa Fluor 700 | NB100-2530AF700 | |||
| Biotin | NB100-2530B | |||
| DyLight 488 | NB100-2530G | |||
| DyLight 550 | NB100-2530R | |||
| DyLight 650 | NB100-2530C | |||
| HRP | NB100-2530H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2530SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-648SS | |||
| Azide and BSA Free | NBP2-81006 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-128SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22122SS | |||
| Azide and BSA Free | NBP2-80719 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-51691SS | |||
| Azide and BSA Free | NBP2-80611 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2289SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47470SS | |||
| Azide and BSA Free | NBP2-80757 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27399 | |||
| Azide and BSA Free | NBP2-27399SS | |||
| BSA Free | NB100-56749SS | |||
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Section of rat hippocampus stained with mouse monoclonal antibody to c-FOS NBP2-50037 in red and counterstained with rabbit polyclonal antibody to FOX3/NeuN. DAPI reveals nuclei of neurons and glia in blue. The hippocampal neurons stain green for FOX3/NeuN and a few also are expressing c-FOS, and so appear orange. These cells were spontaneously active at the time the animal was sacrificed.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and c-Fox knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Mouse Anti-Human c-Fox Monoclonal Antibody (Catalog # NBP2-50037) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for c-Fox at approximately 52 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Knockout-Validated-NBP2-50037-img0005.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Analysis of cell lysates using mouse c-Fos mAb, dilution 1:1,000 (Green), and rabbit GAPDH pAb, dilution 1:20,000 (Red) used as a loading control. [1] protein standard (red), [2] HeLa cells in serum free media. [3] HeLa cells stimulated with 20% fetal bovine serum for 2hrs after 36hrs in serum free media. [4] rat cortical neurons. [5] rat cortical neurons treated with membrane depolarization buffer for 5hrs. Multiple bands at 50-65kDa in stimulated or treated cell lysates correspond to different forms of the c-Fos proten. The single band at 37 kDa represents GAPDH protein.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0007.jpg)
![Immunohistochemistry: c-Fos Antibody (2H2) [NBP2-50037] - pAb 1:1000 (green), DAPI counterstain (blue) on 30 micron cryosection of mouse spinal cord. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-NBP2-50037-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Left: NBP2-50037 staining (green) in HeLa cells, which were treated with serum-starvation for 36 hrs, followed by 2 hrs 20% FBS stimulation (bottom), or PBS treatment (top). Green c-Fos staining only localizes in the nuclei of stimulated cells, but not in un-stimulated cells. Cells are counter-stained with chicken pAb against Vimentin (NB300-223, red). Blue shows DAPI staining of nucleus. Middle: Mouse brain section (45 uM; fixed by transcardial perfusion with 4% PFA) labeled with NBP2-50037 using a standard HRP-DAB staining technique. Cells expressing c-Fos show dark color in nucleus. Right: Mouse cortical section labeled with NBP2-50037 (red) and rabbit polyclonal anti-NeuN (NBP1-92716, green) using IF confocal. Neurons positive for c-Fos and RBFOX3/NeuN appear to be yellow. Inset shows an enlarged image of NBP2-50037 staining. Nuclei are labeled with Dapi (blue).](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0001.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: LOX Antibody [NBP2-24877] - Analysis of mouse ear lysate when LOX antibody (NBP2-24877) was used at 1:1000. The band shown is the expected inactive 50 kD proenzyme.](http://images.novusbio.com/fullsize/LOX-Antibody-Western-Blot-NBP2-24877-img0006.jpg "Western Blot: LOX Antibody [NBP2-24877] - Analysis of mouse ear lysate when LOX antibody (NBP2-24877) was used at 1:1000. The band shown is the expected inactive 50 kD proenzyme.")
![Immunocytochemistry/Immunofluorescence: LOX Antibody [NBP2-24877] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-LOX (NBP2-24877) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-24877-img0007.jpg)
![Immunohistochemistry-Paraffin: LOX Antibody [NBP2-24877] - Analysis of LOX in formalin-fixed, paraffin-embedded mouse skin using an isotype control (top) and NBP2-24877 (bottom) at 1:100.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-Paraffin-NBP2-24877-img0002.jpg)
![Western Blot: LOX Antibody [NBP2-24877] - Analysis of LOX in A) human skin and B) mouse ear skin lysate using NBP2-24877 at 1:500. Goat anti-rabbit IgG HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/LOX-Antibody-Western-Blot-NBP2-24877-img0001.jpg)
![Western Blot: LOX Antibody [NB100-2530] - Detection of LOX in mouse kidney lysate using NB 100-2530 (1:1,000). ECL detection was 15 sec.](http://images.novusbio.com/fullsize/LOX-Antibody-Western-Blot-NB100-2530-img0006.jpg "Western Blot: LOX Antibody [NB100-2530] - Detection of LOX in mouse kidney lysate using NB 100-2530 (1:1,000). ECL detection was 15 sec.")
![Immunocytochemistry/Immunofluorescence: LOX Antibody [NB100-2530] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-LOX [NB100-2530] at a 1:100 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2530-img0009.jpg)
![Immunohistochemistry-Paraffin: LOX Antibody [NB100-2530] - Lysyl Oxidase (LOX) expression in malignant and non-malignant human prostate tissue. Consecutive sections from non-malignant prostate tissue stained with in situ hybridization or immunohistochemistry for LOX. Note that mRNA (brown dots) and protein (brown) expression in individual glands were related, in the stroma in contrast mRNA was generally low but protein often detected (original magnifications x200). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0140985), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-Paraffin-NB100-2530-img0010.jpg)
![Immunohistochemistry: LOX Antibody [NB100-2530] - Human placental villi, 40X. Staining of placental trophoblasts using NB100-2530 at 10 ug/ml.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-NB100-2530-img0007.jpg)
![Simple Western: LOX Antibody [NB100-2530] - Simple Western lane view shows a specific band for Lox in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LOX-Antibody-Simple-Western-NB100-2530-img0008.jpg)
![Immunohistochemistry: LOX Antibody - BSA Free [NB100-2530] - alpha -SMA, LOX, & COL1A1 immunostaining in human thyroid cancers. Representative thyroid tumors serial sections from two different patients stained by IHC for alpha -SMA, COL1A1, & LOX protein expression & localization. In the top panel, the tumor edge/invasive front is specifically shown (scale bar 500 µm), while lower panel has higher magnification (scale bar 200 µm). * clusters of tumor invading cells detaching from the principal tumor mass (T). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906302), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2530_rabbit-polyclonal-lox-antibody-310202415293322.jpg)
![Immunohistochemistry: LOX Antibody - BSA Free [NB100-2530] - Expression of LOX in primary nasopharyngeal carcinoma (IHC staining) Strong expression(a) magnification, ×200; (A) magnification, ×400; Moderate expression: (b) magnification, ×200; (B) magnification, ×400; Weak expression: (c) magnification, ×200; (C) magnification, ×400; Negative: (d) magnification, ×200; (D) magnification, ×400. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.6996), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2530_rabbit-polyclonal-lox-antibody-31020241539749.jpg)
![Immunohistochemistry: LOX Antibody - BSA Free [NB100-2530] - alpha -SMA, LOX, & COL1A1 immunostaining in human thyroid cancers. Representative thyroid tumors serial sections from two different patients stained by IHC for alpha -SMA, COL1A1, & LOX protein expression & localization. In the top panel, the tumor edge/invasive front is specifically shown (scale bar 500 µm), while lower panel has higher magnification (scale bar 200 µm). * clusters of tumor invading cells detaching from the principal tumor mass (T). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906302), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2530_rabbit-polyclonal-lox-antibody-310202415395919.jpg)
![Immunohistochemistry-Paraffin: LOX Antibody - BSA Free [NB100-2530] - Elastin & elastin-related proteins. Tile scans of sheep aortic valve sections stained with Russell Movat's pentachrome (mature elastic fibers in black) & antibodies against proteins involved in elastic fiber formation, including the core protein (tropo)elastin, fibronectin, the microfibrillar proteins fibrillin-1 & fibrillin-2, & cross-linking proteins fibulin-4, fibulin-5, lysyl oxidase (LOX), & Elastin microfibril interfacer 1 (EMILIN-1). Scale bars, 1 mm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30159315), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2530_rabbit-polyclonal-lox-antibody-310202415395921.jpg)
![Immunohistochemistry-Paraffin: LOX Antibody - BSA Free [NB100-2530] - Lysyl Oxidase (LOX) expression in malignant & non-malignant human prostate tissue.(A) Representative immunohistochemical staining of LOX (brown) in sections of non-malignant prostate tissue specimens (TINT epithelium & TINT stroma) from two prostate cancer patients (original magnifications x 200). Case A show weak epithelial staining (score 1) & Case B strong epithelial staining (score 3). (B) Consecutive sections from non-malignant prostate tissue stained with in situ hybridization or immunohistochemistry for LOX. Note that mRNA (brown dots) & protein (brown) expression in individual glands were related, in the stroma in contrast mRNA was generally low but protein often detected (original magnifications x200). (C) LOX mRNA expression in non-malignant prostate tissue (TINT) (n = 12), in primary prostate tumor tissue (n = 12), & in castration-resistant bone metastases (CRPC) (n = 30) using Illumina gene expression array. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26501565), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2530_rabbit-polyclonal-lox-antibody-310202415532099.jpg)
![Immunohistochemistry-Paraffin: LOX Antibody - BSA Free [NB100-2530] - Lysyl Oxidase (LOX) expression in malignant & non-malignant human prostate tissue.(A) Representative immunohistochemical staining of LOX (brown) in sections of non-malignant prostate tissue specimens (TINT epithelium & TINT stroma) from two prostate cancer patients (original magnifications x 200). Case A show weak epithelial staining (score 1) & Case B strong epithelial staining (score 3). (B) Consecutive sections from non-malignant prostate tissue stained with in situ hybridization or immunohistochemistry for LOX. Note that mRNA (brown dots) & protein (brown) expression in individual glands were related, in the stroma in contrast mRNA was generally low but protein often detected (original magnifications x200). (C) LOX mRNA expression in non-malignant prostate tissue (TINT) (n = 12), in primary prostate tumor tissue (n = 12), & in castration-resistant bone metastases (CRPC) (n = 30) using Illumina gene expression array. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26501565), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2530_rabbit-polyclonal-lox-antibody-310202415533822.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0004.jpg "Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.")
![Western Blot: VEGF Antibody (VG76e) [NB100-648] - Analysis of VEGF in human kidney protein (30ug).](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Western-Blot-NB100-648-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: VEGF Antibody (VG76e) [NB100-648] - Immunofluorescent analysis of VEGF using NB100-648. This image submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunocytochemistry-Immunofluorescence-NB100-648-img0007.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC-P analysis of VEGF in sheep tonsil using NB100-648. This image was submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0006.jpg)
![Western Blot: Mouse Monoclonal VEGF Antibody (VG76e) [NB100-648] - Bone lysate homogenate from goats. SDS-PAGE with 0.3 mg of total protein from the homogenate per well. VEGF, NB100-648, was used at a dilution of 1:1000 in TBS Tween and 5% milk powder. The protein was labeled at 40 kDa. Quantification of VEGFA in bone graft in the tibia of intrailiac cellularized goats at different times compared with tibial autograft and untreated bone defect. Evaluation of pre-cellularized graft in iliac crest in the treatment of bone defects in the tibia of goats. G1: cellularized graft for 4 weeks applied to tibial bone defect, G2: cellularized graft for 6 weeks applied to tibial bone defect, G3: cellularized graft for 8 weeks applied to tibial bone defect, G4: tibial autograft and G5: untreated bone defect. All groups were evaluated 120 days after graft implantation. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-648_mouse-monoclonal-vegf-antibody-vg76e-western-blot-2952025142053..jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-128] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti AHR [NB100-128] at a 1:100 dilution overnight at 4C and detected with an anti-goat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-128-img0004.jpg "Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-128] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti AHR [NB100-128] at a 1:100 dilution overnight at 4C and detected with an anti-goat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: AHR Antibody [NB100-128] - Analysis of FFPE human liver using 1:200 conc. of AHR antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunohistochemistry-Paraffin-NB100-128-img0006.jpg)
![Gel Super Shift Assays: AHR Antibody [NB100-128] - EMSA validation of AHR antibody on U937 cells nuclear protein. Image submitted by verified customer - see review for protocol details.](http://images.novusbio.com/fullsize/AHR-Antibody-Gel-Super-Shift-Assays-NB100-128-img0003.jpg)
![Western Blot: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Whole cell protein from HUVEC was separated on a 7.5% gel polyacrylamide gel and transferred to PVDF membrane. The membrane was probed with anti-CD105 antibody at 2 ug/ml and detected with an anti-mouse HRP labeled secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Endoglin-CD105-Antibody-3A9-Western-Blot-NBP2-22122-img0006.jpg "Western Blot: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Whole cell protein from HUVEC was separated on a 7.5% gel polyacrylamide gel and transferred to PVDF membrane. The membrane was probed with anti-CD105 antibody at 2 ug/ml and detected with an anti-mouse HRP labeled secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Human endometrial stromal cells stained with Endoglin/CD105 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/Endoglin-CD105-Antibody-3A9-Immunocytochemistry-Immunofluorescence-NBP2-22122-img0014.jpg)
![Immunohistochemistry-Paraffin: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Immunohistochemical staining of endoglin (CD105) in B16F10 murine melanoma tumor model. IHC-P image submitted by a verifed customer review.](http://images.novusbio.com/fullsize/Endoglin-CD105-Antibody-3A9-Immunohistochemistry-Paraffin-NBP2-22122-img0013.jpg)
![Western Blot: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Analysis using CD105 mAb against HEK293 (1) and CD105 (AA: 331-567)-hIgGFc transfected HEK293 (2) cell lysates.](http://images.novusbio.com/fullsize/CD105-Antibody-3A9-Western-Blot-NBP2-22122-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Analysis of HepG2 cells using CD105 mouse mAb (green). DRAQ5 fluorescent DNA dye (blue). Actin filaments have been labeled with Alexa Fluor555 phalloidin (red).](http://images.novusbio.com/fullsize/CD105-Antibody-3A9-Immunocytochemistry-Immunofluorescence-NBP2-22122-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - HMSC cells stained with anti-CD105 antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Endoglin-CD105-Antibody-3A9-Immunocytochemistry-NBP2-22122-img0007.jpg)
![Immunohistochemistry-Paraffin: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Analysis of paraffin-embedded kidney cancer tissues (left) and stomach cancer tissues (right) using CD105 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CD105-Antibody-3A9-Immunohistochemistry-Paraffin-NBP2-22122-img0005.jpg)
![ELISA: Endoglin/CD105 Antibody (3A9) [NBP2-22122] - Red: Control Antigen (100 ng), Purple: Antigen (10 ng), Green: Antigen (50 ng), Blue: Antigen (100 ng).](http://images.novusbio.com/fullsize/CD105-Antibody-3A9-ELISA-NBP2-22122-img0001.jpg)
![Western Blot: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Carbonic Anhydrase IX mouse antibody against Hela (1) and A549 (2) cell lysates. Bands were detected at a molecular weight of approximately 50 kDa in both cell lines.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Western-Blot-NBP1-51691-img0006.jpg "Western Blot: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Carbonic Anhydrase IX mouse antibody against Hela (1) and A549 (2) cell lysates. Bands were detected at a molecular weight of approximately 50 kDa in both cell lines.")
![Immunohistochemistry-Paraffin: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Paraffin-embedded lung tissues (left) and colonic tissues (right) using Carbonic Anhydrase IX mouse antibody with DAB staining.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Immunohistochemistry-Paraffin-NBP1-51691-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody (2D3) - BSA Free [NBP1-51691] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Carbonic Anhydrase IX/CA9 Antibody [2D3] (NBP1-51691) at 2ug/ml overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-51691-img0012.jpg)
![Flow Cytometry: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - A surface stain was performed on A431 cells with Carbonic Anhydrase IX/CA9 NBP1-51691 (blue) and a matched isotype control NBP2-27287 (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by DyLight488-conjugated anti-mouse secondary antibody.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Flow-Cytometry-NBP1-51691-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Mouse choroid stained with anti-Carbonic Anhydrase IX antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Immunocytochemistry-Immunofluorescence-NBP1-51691-img0011.jpg)
![Flow Cytometry: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Analysis of NTERA-2 cells using Carbonic Anhydrase IX mouse mAb (green) and negative control (purple).](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Flow-Cytometry-NBP1-51691-img0007.jpg)
![Western Blot: AHR Antibody [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha. Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) and western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean +/- SD of two independent experiments performed in three replicates. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-020-58051-1), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/AHR-Antibody-Knockdown-Validated-NB100-2289-img0014.jpg "<b>Genetic Strategies Validation. </b>Western Blot: AHR Antibody [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha. Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) and western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean +/- SD of two independent experiments performed in three replicates. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-020-58051-1), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: AHR Antibody [NB100-2289] - Staining of Aryl hydrocarbon Receptor in mouse prostate.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunohistochemistry-NB100-2289-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-AHR at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0012.jpg)
![Western Blot: AHR Antibody [NB100-2289] - Detection of AhR in mouse liver cytosol using NB 100-2289.](http://images.novusbio.com/fullsize/AHR-Antibody-Western-Blot-NB100-2289-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - HepG2 cells were fixed for 10 minutes using 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-AHR at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0015.jpg)
![Flow Cytometry: AHR Antibody [NB100-2289] - An intracellular stain was performed on U937 cells with NB100-2289 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/AHR-Antibody-Flow-Cytometry-NB100-2289-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - Aryl hydrocarbon Receptor antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0010.jpg)
![Flow Cytometry: AHR Antibody [NB100-2289] - An intracellular stain was performed on U-87 cells with AHR Antibody NB100-2289B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/AHR-Antibody-Flow-Cytometry-NB100-2289-img0013.jpg)
![Simple Western: AHR Antibody [NB100-2289] - Image shows a specific band for Aryl hydrocarbon receptor in 0.5 mg/mL of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/AHR-Antibody-Simple-Western-NB100-2289-img0011.jpg)
![Western Blot: AHR Antibody - BSA Free [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha . (A) qPCR to detect mRNA level of CYP1A1, NQO1, HO1 & TRXR1 upon 20 h PFT-alpha treatment (20 µM) in MCF7 p53KO cells (upper part) & T47D cells (lower part). Relative expression level of CYP1A1 is shown in log2 scale; relative expression level of NQO1, HO1 & TRXR1 are shown as fold change, both normalized with DMSO treatment. All values represent the mean ± SD of two times independent experiments performed in three replicates. (B) Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) & western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean ± SD of two independent experiments performed in three replicates. (C) DCF-DA staining of ROS levels upon doxorubicin treatment (1 µM, 8 h) with or without PFT-alpha (20 µM, 12 h pre-treatment) in MCF7 p53KO cells transfected with scramble siRNA & siAHR. For quantification of ROS levels (lower panel), the values are reported as percentage relative to DMSO treatment group. (D) qPCR to detect mRNA level of Nrf2 targets NQO1, HO1 & TRXR1 upon 20 h PFT-alpha treatment (20 µM) in MCF7 p53KO cells transfected with scramble siRNA & siAHR. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31974452), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2289_rabbit-polyclonal-ahr-antibody-3102024165720.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. Image from verified customer review. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0010.jpg "Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. Image from verified customer review. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]")
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - WNT11 is induced by hypoxia or hypoxic mimetics in different cell types. Immunoblot analyses of HeLa cells under normal air or hypoxia for 24 hrs. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21520) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Western-Blot-NB100-902HIF2-img0012.jpg)
![Simple Western: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Lane view shows a specific band for HIF-2 alpha in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Simple-Western-NB100-902HIF2-img0009.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - HIF-1alpha is the predominant transcriptional regulator of WNT11 expression during hypoxia. EMSCs isolated from the indicated mouse genotypes were infected with lentivirus expressing GFP or Cre recombinase. Non-infected cells and GFP infected cells served as controls. Immunoblot analyses of EMSCs derived from the indicated genotypes treated with 0.1 mM DMOG for 24 hrs. Attenuated WNT11 expression in Hif-1alpha KO EMSCs (lenti-Cre infected Hif-1af/f). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21520) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Knockout-Validated-NB100-902HIF2-img0013.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Formalin-fixed paraffin-embedded tissue sections of human placenta were probed for HIF-2 alpha/EPAS1 mRNA (ACD RNAScope Probe, catalog #410598; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus Biologicals catalog # NB100-122) at 1:100 dilution with one-hour incubation at room temperature followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to trophoblastic cells. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0014.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Normal ganglia 1 (NG1), normal ganglia 2 (NG2) and IDH-mutant (IDH). Sporadic PGL (Spo. PGL). HIF2 alpha staining. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0127471) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0011.jpg)
![Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of GSK-3 beta in mouse beta cell line (betaTC3) using anti-GSK-3 beta antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Western-Blot-NBP1-47470-img0012.jpg "Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of GSK-3 beta in mouse beta cell line (betaTC3) using anti-GSK-3 beta antibody. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of NIH/3T3 (left) and U251 (right) cells using GSK3 beta mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunocytochemistry-Immunofluorescence-NBP1-47470-img0006.jpg)
![Immunohistochemistry: GSK-3 beta Antibody (3D10) [NBP1-47470] - Fap1-inhibition with SLV peptide increases phosphorylation of Fap1-substrates Fas and GSK-3 beta in a murine xenograft model. SW620 cells injected into flanks of athymic Nude mice & tumor volume was checked biweekly. Mice treated weekly with oxaliplatin (days 0, 7 and 14) & injected daily with Fap1 blocking SLV peptide, VLS control peptide, or treated with SLV or VLS peptide alone (n=12). Tumors were simultaneously harvested when control tumors were >2,000 mm3. SLV peptide increases Gsk3-phosphorylation with/without oxaliplatin. IF detection of total versus phospho- GSK-3 beta performed with DAPI staining of nuclei (areas without gland formation were selected). Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.25401), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunohistochemistry-NBP1-47470-img0014.jpg)
![Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - An intracellular stain was performed on HeLa cells with GSK-3 beta (3D10) antibody NBP1-47470PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Flow-Cytometry-NBP1-47470-img0013.jpg)
![Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis using GSK3 beta mouse mAb against A549 (1), K562 (2), PC-12 (3), NIH/3T3 (4), and HEK293 (5) cell lysates.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Western-Blot-NBP1-47470-img0008.jpg)
![Immunohistochemistry-Paraffin: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of paraffin-embedded human lung cancer (left) and breast cancer tissues (right) using GSK3 beta mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunohistochemistry-Paraffin-NBP1-47470-img0007.jpg)
![Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - Flow cytometric analysis of Hela cells using GSK3 beta mouse mAb (green) and negative control (purple).](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Flow-Cytometry-NBP1-47470-img0005.jpg)
![Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple Western lane view shows a specific band for GSK-3 Beta in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Simple-Western-NBP1-47470-img0009.jpg)
![Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple western analysis of mouse brain tissue (striatum) from 4 month old Tg4150 and wildtype mice. Image courtesy of Dr. Brandi Wasek-Patterson at Baylor Research Institute, Institute of Metabolic Disease.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Simple-Western-NBP1-47470-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases Fas & Gsk3 beta phosphorylation in CD133+ cells in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases Fas phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Fas or CD133 was performed with DAPI staining of nuclei. (B) SLV peptide increases Gsk3 beta phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Gsk3 beta or CD133 was performed with DAPI staining of nuclei. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47470_mouse-monoclonal-gsk-3-beta-antibody-3d10-310202416171462.jpg)
![Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases phosphorylation of Fap1-substrates Fas & Gsk3 beta in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases gland formation in xenograft tumors with or without oxaliplatin. Histology was analyzed by hematoxylin/ eosin staining. Fap1 expression was determined by immunofluorescence. Relative fluorescent intensity (RFI) of Fap1 staining is indicated below relevant panels. (B) SLV peptide increases Fas-phosphorylation in xenograft tumors with or without by oxaliplatin. Immunofluorescent detection of total versus phospho-Fas was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. (C) SLV peptide increases Gsk3 beta -phosphorylation with or without oxaliplatin. Immunofluorescent detection of total versus phospho- Gsk3 beta was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47470_mouse-monoclonal-gsk-3-beta-antibody-3d10-3102024161604.jpg)
![Western Blot: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - Total protein from mouse 3T3 cells treated with and without PDGF (50 ng/mL) for the indicated times was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-AKT1 (NBP2-01725) and 2 ug/mL pS473 AKT1 in 1% BSA in TBST and detected with an anti-mouse HRP secondary antibody using chemiluminescence. Note the detection of phosphorylated AKT1 in response to PDGF treatment compared to total AKT1 protein.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Western-Blot-NB100-56749-img0014.jpg "<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - Total protein from mouse 3T3 cells treated with and without PDGF (50 ng/mL) for the indicated times was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-AKT1 (NBP2-01725) and 2 ug/mL pS473 AKT1 in 1% BSA in TBST and detected with an anti-mouse HRP secondary antibody using chemiluminescence. Note the detection of phosphorylated AKT1 in response to PDGF treatment compared to total AKT1 protein.")
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - WB of phospho AKT using phospho AKT antibody at 2 ug/mL against untreated (lane 1) and PDGF treated (lane 2) NIH-3T3 lysate. HRP conjugated secondary antibody and ECL substrate solution were used for this test. Image using the Azide and BSA Free form of this antibody.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Western-Blot-NB100-56749-img0015.jpg)
![Immunohistochemistry-Paraffin: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - IHC analysis of an FFPE human breast carcinoma tissue section using 1:250 dilution of phospho Ser473 AKT1 antibody (clone 104A282) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of phosphor-AKT (Ser-473) in the cancer cells as well as the stromal cells. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Immunohistochemistry-Paraffin-NB100-56749-img0009.jpg)
![Immunohistochemistry-Frozen: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - Rat mammary carcinoma tissue section stained with AKT1 [p Ser473] Antibody (104A282). IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Immunohistochemistry-Frozen-NB100-56749-img0016.jpg)
![Immunohistochemistry-Paraffin: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - IHC analysis of an FFPE human breast carcinoma tissue section using 1:250 dilution of pSer473 AKT1 antibody (clone 104A282) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of phosphor-AKT (Ser-473) in the cancer cells as well as the stromal cells. Some cancer cells depicted nuclear stianing also. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Immunohistochemistry-Paraffin-NB100-56749-img0010.jpg)